Marksans Pharma Limited saw a 2% surge in its stock price after receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.
This generic version of Bayer Healthcare’s Clartin tablet is indicated for the treatment of allergic rhinitis and upper respiratory tract allergies. Available for over-the-counter use, this approval marks a significant milestone for Marksans Pharma, enhancing its portfolio in the allergy treatment market.
As of 12:09 pm, Marksans Pharma shares were trading 1.89% higher at Rs 315.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
